Skip to content
value.today

VerImmune, Inc.

🇺🇸 Baltimore, Maryland, USABiotechnologyFounded 2020
Total raised
$6 M
2 rounds on record
Latest round
$5 M
Aug 2024
First round on record
Mar 2022
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of VerImmune, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2024$5 MNo. 2$2 to $10 million

VerImmune, Inc.: Raise no. 2, Aug 2024

Investors in this round

6 investors had bought by the notice of Sep 25, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $8 M offered; $4 M still to sell
Smallest investment taken
$22,806
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joshua Wang · Executive Officer, Director, Promoter
  • Che Koh Hsu · Director
  • Cynthia Koh Poh · Director
  • Haolin Sung · Director
  • Kevin Koh Rongsheng · Director
  • Marta Koh New · Director
  • Roger Koh Pomerantz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua Weiyuan Wang, Founder, President & CEO. Source: SEC Form D, newest notice filed Sep 25, 2024. Read the notice at the SEC.

equity, optionsSEC
Mar 2022$1 MNo. 1Under $2 million

VerImmune, Inc.: Raise no. 1, Mar 2022

Investors in this round

9 investors had bought by the notice of Mar 31, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $1 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$125,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Maryland

People named in the notice

  • John Weiyuan Troyer · Executive Officer
  • Joshua Weiyuan Wang · Executive Officer, Director, Promoter
  • Cynthia Weiyuan Poh · Director
  • Kevin Koh Rongsheng · Director
  • Roger Koh Pomerantz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua Weiyuan Wang, President. Source: SEC Form D, newest notice filed Mar 31, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • VerImmune, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2024).

    SEC Form D · Sep 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2024

That is all the official record says: VerImmune, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of VerImmune, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by VerImmune, Inc.
NameRoleNamed in
Joshua WangExecutive officerSep 2024
John Weiyuan TroyerExecutive officerMar 2022
Joshua Weiyuan WangExecutive officerMar 2022
Che Koh HsuDirectorSep 2024
Cynthia Koh PohDirectorSep 2024
Haolin SungDirectorSep 2024
Joshua WangDirectorSep 2024
Kevin Koh RongshengDirectorSep 2024
Marta Koh NewDirectorSep 2024
Roger Koh PomerantzDirectorSep 2024
Cynthia Weiyuan PohDirectorMar 2022
Joshua Weiyuan WangDirectorMar 2022
Joshua WangPromoterSep 2024
Joshua Weiyuan WangPromoterMar 2022